IN Brief:
- Nestlé plans a R$600m, 11,000m² infant-formula factory beside its existing dairy complex in Ituiutaba, Minas Gerais.
- Construction is scheduled to begin in 2027, with production expected from the second half of 2028.
- The plant forms part of R$2bn of Brazilian nutrition and health investment and is intended to increase domestic supply currently supported partly by imports.
Nestlé plans to invest R$600m in a new infant-formula factory at Ituiutaba in Minas Gerais, adding dedicated production capacity beside one of its established Brazilian dairy operations.
The approximately 11,000m² factory is scheduled to begin construction in 2027 and enter production during the second half of 2028. Nestlé expects around 100 permanent jobs once the plant is operating, with hundreds more associated with the construction phase.
The investment forms part of R$2bn allocated to Nestlé’s Nutrition and Health business in Brazil through 2028. That programme in turn sits within the company’s broader R$7bn Brazilian investment cycle covering 2025 to 2028.
The new factory will be built beside Nestlé’s existing Ituiutaba dairy complex, which local reporting describes as the company’s largest dairy operation in Latin America. The current site already manufactures powdered-milk products, giving the new development access to an established industrial location rather than requiring a completely separate manufacturing base.
Nestlé intends the additional capacity to increase supply to the Brazilian market, which is currently served partly through imported infant-formula products. The company has also identified potential future export opportunities once domestic production is established.
Initial production is expected to include lines from the Nestogeno, Nestonutri and Ninho ranges. The investment therefore brings products currently associated with Nestlé’s nutrition portfolio into a site already experienced in large-scale dairy processing.
Infant-formula production nevertheless requires a different level of manufacturing control from conventional powdered milk. Formulation, ingredient handling, hygiene zoning, environmental control, process validation and finished-product release all have to operate within stringent specifications for products intended for young children.
Those requirements influence the design of the factory as much as its nominal capacity. Air handling, segregation, cleaning systems, laboratory support and traceability have to be integrated with the main production process rather than added as secondary quality measures.
The powder format also places significant emphasis on moisture control and protection after processing. Once product reaches its required formulation and physical specification, downstream handling and packaging have to prevent contamination or deterioration before release.
Building beside an established dairy complex can provide advantages in utilities, logistics, raw-material handling and technical skills. Existing milk-processing knowledge can also support recruitment and maintenance, although infant-formula operations will still require dedicated validation and control systems appropriate to the category.
Ituiutaba therefore gives Nestlé a way to expand nutrition manufacturing around an existing industrial base while preserving separate process requirements for the new products. The location also avoids creating every supporting service and supplier connection from the ground up.
Nestlé already produces infant nutrition at its Araçatuba industrial complex in São Paulo state and plans additional production investment there. The Minas Gerais project creates another dedicated manufacturing location rather than concentrating all future Brazilian capacity at one site.
That diversification can add resilience as well as volume. Additional validated production capacity gives the company more options when individual factories are under maintenance or when demand changes between product families, although infant-formula production cannot simply be transferred between plants without the necessary approvals and manufacturing controls.
The domestic-supply objective is commercially important. Importing finished formula exposes the Brazilian business to international freight, exchange rates and longer replenishment times, while local production brings more of the manufacturing schedule under the company’s regional control.
Localisation does not automatically make production cheaper, particularly during the early years of a capital-intensive plant. The economics will depend on factory utilisation, raw-material costs, efficiency and the volume that can be shifted from imported supply into the new operation.
Nestlé’s choice to commit R$600m nevertheless indicates that it expects sufficient long-term demand to support dedicated capacity. Nutrition and health has been identified by the company as a strategic growth area globally as well as in Brazil.
The project also expands a Brazilian manufacturing programme announced before the latest factory detail. Nestlé had already identified Ituiutaba for further investment in nutrition products, with infant formula and growing-up milk among the areas targeted within its wider R$7bn national capital cycle.
The more detailed September plan establishes the physical scale and timetable of that commitment. An 11,000m² plant moves the project beyond a general capacity intention and into a defined factory programme with construction beginning next year.
There remains a substantial engineering period before commercial production. Construction, equipment installation, commissioning and process qualification have to be completed before the scheduled H2 2028 start, while products will also have to meet the regulatory requirements applying to infant nutrition in Brazil.
Approximately 700 construction-phase jobs have been cited locally, compared with around 100 permanent positions once the site is operating. The difference reflects the capital-intensive nature of modern food manufacturing, where large project workforces give way to more automated routine operations supported by production, engineering and quality specialists.
If the timetable holds, Ituiutaba will become a second major Brazilian base for Nestlé infant-formula production alongside Araçatuba. The immediate industrial rationale is straightforward: replace part of an imported supply requirement with local capacity while building that capability next to an established dairy-processing operation.
The longer-term measure will be utilisation. By 2028, Nestlé will have committed R$2bn to its Brazilian nutrition and health business, and the new factory will have to convert that capital into reliable local production rather than simply add another nameplate capacity figure to the network.
